Geron Corp
GERNHealthcare|Biotechnology|USA
$1.50
-0.07 (-4.15%)
Tangible Book
$0.36
Upcoming Data Readouts (4)
Feb 2027
Est. completion
P1Myelofibrosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT05371964n=36
Mar 2028
Est. completion
P1Recurrent Childhood Acute Myeloid Leukemia
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787n=36
Jun 2028
Est. completion
P3Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156n=327
Jun 2030
Est. completion
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2025
P2
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT05583552Oct 2023
P2P3
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661